HEATHER FRYE: Open Payments
NPI 1366752073 · DOVER, DE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$647 in 31 payments from 12 companies in 2025. Trend: 2023 $149 · 2024 $414 · 2025 $647
Food & beverage: $647
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 4 | $113 |
| Teva Pharmaceuticals USA, Inc. | 5 | $90 |
| Otsuka America Pharmaceutical, Inc. | 4 | $88 |
| Vanda Pharmaceuticals Inc. | 4 | $86 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $71 |
| Neurocrine BioSciences, Inc. | 2 | $40 |
| Lundbeck LLC | 2 | $36 |
| E.R. Squibb & Sons, L.L.C. | 2 | $32 |
| Corium, LLC | 1 | $27 |
| Axsome Therapeutics, Inc. | 1 | $26 |
Products named: ARISTADA, REXULTI, AUSTEDO XR, CAPLYTA, HETLIOZ, INGREZZA, COBENFY, LYBALVI.
Industry payments across DE — which companies pay providers there.
